A pill form of weight-loss drug Wegovy, manufactured by Danish drugmaker Novo Nordisk, is now available in the U.S., giving Americans access to an oral medication to treat obesity. The starting dose of the daily Wegovy pill, at 1.5 milligrams, is now available for $149 per month for self-paying patients, Novo Nordisk announced on Monday. A 4 mg dose of the medication is available for the same price through April 15, after which the cost will rise to $199.
Main Idea: Novo Nordisk has launched a weight-loss pill version of Wegovy in the U.S., giving patients a new oral option for obesity treatment.
Key Points:
The Wegovy pill may cause nausea and diarrhea, and the monthly price could still be too high for many households.
Novo Nordisk’s pill gives people with obesity a new, easier-to-take option that could help some patients lose weight.
Rate how each entity in this article affected the American people.
Primary company launching the Wegovy pill in the United States and setting the pricing and rollout details.
Federal regulator that approved the pill version of Wegovy and is central to the product’s U.S. availability.
Named Novo Nordisk executive quoted about the launch and its significance.
Named competitor whose obesity pill is mentioned as being under FDA review.
Comments here are the same thread shown when this article appears in The Pulse.
No comments on this article yet.
Sign in to comment